|
|
Volumn 23, Issue 15, 2005, Pages 3645-3646
|
|
Resisting a fundamentalist policy [12]
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
GEMCITABINE;
TAXANE DERIVATIVE;
ANTINEOPLASTIC AGENT;
CANCER CHEMOTHERAPY;
CANCER PATIENT;
CANCER RESEARCH;
CANCER SURVIVAL;
CHEMOSENSITIVITY;
CLINICAL PRACTICE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
HEALTH CARE POLICY;
HUMAN;
IN VITRO STUDY;
LETTER;
LUNG NON SMALL CELL CANCER;
MEDICAL DECISION MAKING;
MEDICAL SOCIETY;
MEDICAL SPECIALIST;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
COMPARATIVE STUDY;
DRUG RESISTANCE;
DRUG SCREENING;
MANAGEMENT;
NEOPLASM;
NOTE;
ONCOLOGY;
PRACTICE GUIDELINE;
SENSITIVITY AND SPECIFICITY;
STANDARD;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
DRUG RESISTANCE, NEOPLASM;
DRUG SCREENING ASSAYS, ANTITUMOR;
GUIDELINES;
HUMANS;
MEDICAL ONCOLOGY;
NEOPLASMS;
POLICY MAKING;
SENSITIVITY AND SPECIFICITY;
UNITED STATES;
|
|
EID: 20644432866
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2005.05.270 Document Type: Letter |
|
Times cited : (4)
|
|
References (2)
|
